Response to “Tailored Use of Avacopan in a Case With Refractory Antineutrophil Cytoplasmic Autoantibody-Associated Renal Vasculitis and Concominant Complement System Activation”...

por van Leeuwen, Jolijn R., Rabelink, Ton J., Teng, Y.K. Onno
Publicado 2022

Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis

por van Leeuwen, Jolijn R, Popov, Tamara, Obergfell, Achim, Rabelink, Ton J, Teng, Y K Onno
Publicado 2023

The impact of reclassification by the 2022 ACR/EULAR classification criteria on risk factors for relapse in patients with ANCA-associated vasculitis

por van Leeuwen, Jolijn R, Hafemann, Sophia, van der Boog, Paul, van der Woude, Diane, Rabelink, Ton, Teng, Y K Onno
Publicado 2023

Compassionate Use of Avacopan in Difficult-to-Treat Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

por van Leeuwen, Jolijn R., Bredewold, Obbo W., van Dam, Laura S., Werkman, Stella L., Jonker, Jacqueline T., Geelhoed, Miranda, Langeveld, Antonius P.M., Remmelts, Hilde H.F., van den Broecke, Maud M., Ray, Argho, Rabelink, Ton J., Teng, Y.K. Onno
Publicado 2021

ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial

por Dirikgil, Ebru, van Leeuwen, Jolijn R, van Dam, Laura S, Bredewold, Obbo W, Ray, Argho, Jonker, Jacqueline T, Soonawala, Darius, Remmelts, Hilde H F, van Dam, Bastiaan, Bos, Willem Jan, van Kooten, Cees, Rotmans, Joris, Rabelink, Ton, Teng, Y K Onno
Publicado 2022